CURRICULUM VITAE Robert Strohal, MD - EWMA

• Marie Curie Fellowship Association – Platform of the European Commission for
scientists having received a Marie Curie Fellowship
• European Assotiation of Dermatology and Venerology – EADV
3/2010
� Laboratory-based Research Projects
• In-situ immunophenotyping of the cutaneous melanoma-associated
inflammatory infiltrate, sponsor: Commission of Cancer Research of the University
of Vienna Medical School, 12/1/92 - 11/30/93
• Molecular studies of the T-cell receptor gene repertoire and polymorphism from
melanoma infiltrating lymphocytes, sponsor: Austrian Federal Bank- project No.
4568, 5/1/93 - 5/30/95
• Selectivity and transcription/expression kinetics of melanoma-associated
antigens: potential for their regulation in-vitro and in-vivo, sponsor: Austrian
Federal Bank- project No. 5562, 12/1/95 - 10/1/97
• Oncogenesis of malignant melanoma – a molecular approach, sponsor:
Commission of Cancer Research of the University of Vienna Medical School, 4/1/96 -
3/31/98
• Comparative studies on anti-tumor activities of Interferon-α2b and monopegylated
Interferon-α regarding their immuno-modulating and antiproliferative
effects on human melanocytes and melanoma cells, sponsor:
AESCA, 10/1/1998 -12/31/1998
• Delineation of the clonality of malignant melanoma via molecular mapping of
melanoma-associated antigens, sponsor: University Foundation of the City of
Vienna - project No. 54/98, 12/1/1998 - 12/31/1999
• Induction of melanoma-based HLA, CD80 and tumor antigen expression by
Interferon-α, sponsor: Austrian Federal Bank - project No. 7583, 1/1/99 - 3/1/00
• Melanoma-associated antigens as potential tumor vaccines – a molecular
approach, sponsor: University Award of the Viennese Chamber of Economics,
2/11/99 -1/30/00
• Melanoma antigen transduced autografts as a new form of tumor vaccine,
sponsor: Marie Curie fellowship Cat. 40 for experienced researchers by the European
Commission Programm “Improving Human Potential” – project MCFI-2000-001668,
7/01 – 1/02
• Dystrophin - a new potential biomarker for the malignant transformation of
epithelial and melanocytic tissues, sponsor: Austrian Federal Ministry of
Education, Science and Cultural Affairs, 10/00-3/02
• In vitro, microbiological, pilot study of Acticoat ® as new anti-MRSA barrier or
therapeutic option for external critically MRSA colonized wounds, sponsor:
Smith + Nephew Austria, 4/02 - 6/02
• Silver Dressings and MRSA – a comparative microbiological in-vitro trial,
sponsor: Smith and Nephew Global, 11/03-4/04
8